光疗修改了血液学标记,而没有诱导新生儿的炎症:一项回顾性观察性研究
相关实验视频
Updated: May 12, 2026
13:13
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
14.2K
Ceren Can1, Şahin Hamilçıkan2, Yakup Karakurt3
1Department of Pediatric Immunology and Allergy, University of Health Sciences, Istanbul, Turkey. ceren.can@sbu.edu.tr.
European journal of pediatrics
|June 6, 2025
概括
光疗改变新生儿血液学指数,增加红细胞分布宽度与血小板计数 (RDW/PLT) 和RDW与淋巴细胞计数 (RDW/LF) 的比率,表明没有全身炎症的氧化应激. 这些发现支持光疗疗法.
科学领域:
- 新生儿医学 新生儿医学
- 血液学 血液学 血液学
- 光疗研究 光疗研究
背景情况:
- 光疗是新生儿高胆固醇血症的标准治疗方法,有效治疗黄.
- 光疗对血液学指数的潜在影响,特别是新生儿的氧化应激和炎症,需要进一步阐明.
- 现有研究表明,光疗可能会影响氧化应激路径,但其系统性炎症影响仍然不太了解.
研究的目的:
- 研究光疗对特定血液学比率的影响,这些比率表明新生儿的氧化应激.
- 通过分析各种炎症标志物,评估光疗是否诱导全身炎症.
- 评估血液学比率作为光疗对氧化应激影响的可访问指标的潜力.
主要方法:
- 一项追溯观察性研究,涉及96名接受光疗治疗的新生儿.
- 血液学比率的分析,包括红细胞分布宽度与血小板计数 (RDW/PLT),红细胞分布宽度与淋巴细胞计数 (RDW/LF) 以及血小板分布宽度与血小板计数 (PDW/PCT) 在治疗前后.
- 系统性炎症标志物的比较,例如中性粒细胞与淋巴细胞的比率 (NLR),血小板与淋巴细胞的比率 (PLR) 和使用威尔科克森签名等级测试的其他标志物.
主要成果:
- 光疗显著增加了RDW/PLT (中位数为0.11至0.14) 和RDW/LF (2.98至3.62) 的比率.
- 在光疗后,PDW/PCT比率 (42.1至36.4) 显著下降.
- 检测到系统性炎症标志物没有显著变化,表明光疗没有引起系统性炎症反应.
结论:
- 光疗诱导局部血液学变化,可能反映氧化活性,而不会引起新生儿的全身炎症.
- RDW/PLT和RDW/LF比率显示为光疗氧化反应的可访问指标.
- 研究结果支持光疗对满期和近期新生儿的血液学安全性,尽管对极度早产婴儿需要进一步的研究.
相关概念视频
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...